Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy

Journal of the Medical Association of Thailand

Volumn 89, Issue SUPPL. 4, 2006, Pages

  Pradermdee, Panadda ^a   Manusirivithaya, Sumonmal ^a   Tangjitgamol, Siriwan ^a   Thavaramara, Taovalai ^a   Sukwattana, Pacheun ^a  

^a Bangkok Metropolitan Administration   (Thailand)

Author keywords

Age; Chemotherapy induced emesis; Cisplatin; Dexamethasone; Ondansetron

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; ONDANSETRON; PACLITAXEL;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG EFFECT; GYNECOLOGIC CANCER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; RISK FACTOR; SINGLE DRUG DOSE; UTERINE CERVIX CANCER; UTERINE TUBE CARCINOMA; UTERUS CANCER; VOMITING;

ACUTE DISEASE; ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; NAUSEA; ONDANSETRON; SEROTONIN ANTAGONISTS; VOMITING;

EID: 33846664496     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Morrow GR. Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin 1989; 39: 89-104.
2. Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP, et al. Chemotherapy-induced nuasea and vomiting. Clin J Oncol Nurs 2002; 6: 94-102.
3. rd ed. Philadelphia: Lippincott Williams &Wilkins; 2001: 477-80.
4. rd ed. Philadelphia: Elsevier; 2004: 759-69.
5. th ed. Hamiltion: B.C. Decker; 2000: 2243-50.
6. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 1999; 17: 2971-94.
7. Grunberg SM, Hesketh PJ. Control of chemotherapy -induced emesis. N Engl J Med 1993; 329: 1790-6.
8. Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, et al. Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990; 322: 816-21.
9. De Mulder PH, Seynaeve C, Vermorken JB, Van Liessum PA, Mols-Jevdevic S, Allman EL, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40.
10. Licitra L, Spinnazze S, Roila F. Antiemetic therapy. Crit Rev Oncol Hemato 2002; 43: 93-101.
11. Cunningham D, Turner A, Hawthorn J, Rosin RD. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet 1989; 1(8650): 1323.
12. Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin J, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997; 15: 2966-73.
13. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5.
14. Roila F, Tonato M, Cognetti F. Prevention of cisplatin-induced emesis: a double blind multicentre randomized cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-8.
15. Hainsworth JD, Hesketh PJ. Single dose ondansetron for the prevention of cisplatin-induced emesis: efficacy result. Semin Oncol 1992; 19(6 Suppl 15): 14-9.
16. Seynaeve C, Schuller J, Buser K, Porteder H, Belle SV, Sevelda P, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A Multicentre, double-blind, randomized, parallel group study. Br J Cancer 1992; 66: 192-7.
17. Brown GW, Paes D, Bryson J, Freeman AJ. The effectiveness of a single intravenous dose of ondansetron. Oncology 1992; 49: 273-8.
18. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimens versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10: 1969-75.
19. Hesketh PJ, Beck T, Uhlenhopp M, Kris MG, Hainsworth JD, Harker WG, et al. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen. J Clin Oncol 1995; 13: 2117-22.
20. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-9.
21. Pectasides D, Mylonakis A, Varthalitis J, Kostopoulou M, Constantinou A, Papazachariou K, et al. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis. Oncology 1997; 54: 1-6.
22. Manusirivithaya S, Chareoniam V, Isariyodom P, Sungsab D. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone- lorazepam in the control of cisplatin induced emesis. J Med Assoc Thai 2001; 84: 966-72.
23. The Italian Group for Antiemetic Research. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. J Clin Oncol 1993; 11: 2396-404.
24. Bryson JC. Clinical safety of ondansetron. Semin Oncol 1992; 19(6 Suppl 15): 26-32.